On this page Agenda Applications for consideration at this meeting 1196.1 Repetitive Trans cranial Magnetic Stimulation (rTMS) for the treatment of depression (resubmission) 1440.1 PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer 1454 Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment 1476 Genetic testing for childhood syndromes 1485 Sentinel Lymph Node Biopsy for intermediate thickness melanoma 1491 Vagus nerve stimulation for chronic major depressive episodes 1492 Non-invasive prenatal testing (NIPT) 1493 Transarterial radioembolisation with yttrium-90 (TARE-Y) for the treatment of unresectable hepatocellular carcinoma 1504 Heritable mutations which increase risk in colorectal and endometrial cancer 1511 Extended half-life (EHL) blood clotting factors VIII + IX Related information Committee: Medical Services Advisory Committee (MSAC)